There may still be a misunderstanding here it seems.
These similar indications I have mentioned, listed in the presentation below, are also considered to be addressed by Cx601:
http://tigenix.com/wp-content/themes/tigenix/images/TiGenix_Corporate_Presentation.pdf
"Local treatment of fistulae" you have highlighted in your first post means an MSC injection right into the fistula (as opposed to an IV infusion of Prochymal in Crohn's Disease).
See page 9 of the presentation above (images are probably too disturbing for HC guidelines).
Prochymal is about to be tested in Crohn's Disease (CD), which addresses a much larger market than complex perianal fistulas.
The link you have quoted gives a bit of an indication:
"are a common complication of CD disease that roughly 20% of CD patients will face during their lifetime".
https://decisionresourcesgroup.com/...ed-cost-effective-fistulizing-crohns-disease/
As you can see, these are two separate disease targets with two separate MSC products trying to address them.
Hope that helps.
Add to My Watchlist
What is My Watchlist?
